Table 1.
Periprostatic adipose tissue (PPAT) human cohorts and methodologies employed. BMI—Body Mass Index; BPH—Benign Prostate Hyperplasia; PCa—Prostate Cancer; PSA—Prostate-Specific Antigen; SD—Standard Deviation. Data represent the mean ± SD of each group.
| Methodology | BMI | Parameter | BPH Group | PCa Group |
|---|---|---|---|---|
| RT-qPCR Cohort 1 (n = 20) |
Normo-weight | n | 5 | 5 |
| BMI (kg/cm2) | 23.76 ± 1.71 | 23.47 ± 1.39 | ||
| PSA (ng/mL) | 4.28 ± 5.67 | 6.73 ± 4.28 | ||
| Gleason score | - | 7 ± 0 | ||
| Age | 69.9 ± 5.59 | 60.8 ± 4.96 | ||
| PI-RADS | 2.67 ± 1.15 | 4.25 ± 0.50 | ||
| Obesity | n | 5 | 5 | |
| BMI (kg/cm2) | 31.05 ± 2.09 | 33.63 ± 1.25 | ||
| PSA (ng/mL) | 9.60 ± 17.04 | 14.29 ± 8.14 | ||
| Gleason score | - | 7 ± 0 | ||
| Age | 69.4 ± 7.66 | 62.2 ± 3.42 | ||
| PI-RADS | 2 ± 0 | 4.20 ± 1.30 | ||
| Microfluidic-based qPCR array Cohort 2 (n = 48) |
Normo-weight | n | 6 | 14 |
| BMI (kg/cm2) | 24.161 3.20 | 23.80 1.12 | ||
| PSA (ng/mL) | 3.99 5.12 | 8.43 7.35 | ||
| Gleason score | - | 7 | ||
| Age | 69.33 ± 5.04 | 59.45 ± 5.15 | ||
| PI-RADS | 2.33 ± 0.81 | 4.51 ± 0.53 | ||
| Obesity | n | 14 | 14 | |
| BMI (kg/cm2) | 31.26 ± 2.07 | 31.13 ± 1.01 | ||
| PSA (ng/mL) | 6.99 ± 10.31 | 7 ± 4.95 | ||
| Gleason score | - | 6.85 ± 0.37 | ||
| Age | 69.22 ± 6.62 | 58.85 ± 5.33 | ||
| PI-RADS | 2 ± 0 | 4.27 ± 0.90 |